JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hyden, E. C.
Right arrow Articles by Petrovich, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hyden, E. C.
Right arrow Articles by Petrovich, Z.

The Journal of Thoracic and Cardiovascular Surgery, Vol 96, 237-241, Copyright © 1988 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

External beam and intraluminal radiotherapy in the treatment of carcinoma of the esophagus

EC Hyden, B Langholz, T Tilden, K Lam, G Luxton, M Astrahan, J Jepson and Z Petrovich
Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles.

During a 10-year period, 46 patients with unresectable or inoperable carcinoma of the esophagus were treated with teletherapy-brachytherapy combination at the University of Southern California School of Medicine. Stage distribution was as follows: stage I, 5 (11%) patients; stage II, 23 (50%) patients; stage III, six (13%) patients; and stage IV, 12 (26%) patients. Thirteen patients were treated for recurrent disease, including 11 patients initially treated with teletherapy and two who had had surgical resection. Radiotherapy was given by teletherapy in 33 and brachytherapy in all 46 patients. An average tumor dose was 50 Gy with teletherapy and 20 Gy per application with brachytherapy. There were 25 patients who had more than one brachytherapy application. The 5-year actuarial survival rate for 28 patients with stage I or II disease was 12%, with a median of 13 months. This compared with no 5-year survivals and a median survival of 10 months for the 18 patients with stage III or IV disease. Failure at the primary site was seen in 16 (35%) patients. Complete response was seen in 20%, partial response in 76%, and no response in 4%. Treatment was well tolerated. Complications included esophageal stenosis in two patients and tracheoesophageal fistula in one. Teletherapy- brachytherapy combination is an effective treatment in the management of unresectable or inoperable carcinoma of the esophagus.


This article has been cited by other articles:


Home page
JCOHome page
S. Ishikura, K. Nihei, A. Ohtsu, N. Boku, S. Hironaka, K. Mera, M. Muto, T. Ogino, and S. Yoshida
Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus
J. Clin. Oncol., July 15, 2003; 21(14): 2697 - 2702.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
N Fuwa, Y Nomoto, K Shouji, T Kodaira, M Kamata, and Y Ito
Therapeutic effects of simultaneous intraluminal irradiation and intraluminal hyperthermia on oesophageal carcinoma
Br. J. Radiol., August 1, 2001; 74(884): 709 - 714.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1988 by The American Association for Thoracic Surgery.